Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus

May 18, 2023
Medical Communications Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care …

News

US appeals court hears arguments in abortion pill case

May 18, 2023
Medical Communications Obstetrics & Gynaecology, abortion, medication abortion, mifepristone, reproduction

The ongoing court battle surrounding the contested approval of mifepristone, one of the drugs used in medication abortions, has now …

News

Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins

May 18, 2023
Research and Development Aitia, Digital Twins, Oncology, Pancreatic cancer, Servier

French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital …

News

Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer

May 18, 2023
Research and Development Asieris Pharmaceuticals, Diagnostics, Oncology, Uroviu, bladder cancer, oncology

US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they have entered into a strategic …

News

Nemours Children’s Health selected to conduct first gene therapy for Morquio A syndrome

May 17, 2023
Research and Development Morquio A syndrome, NIH, Nemours Children's Health, Paediatrics, gene therapy

Nemours Children’s Health, based in Delaware, US, has been chosen by the Foundation for the National Institutes of Health (FNIH) …

News

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

May 17, 2023
Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …

News

NICE recommends nine digital treatment options for depression and anxiety

May 17, 2023
Medical Communications NICE, Neurology, anxiety, depression, digital health, mental health

The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety …

News

FDA grants Priority Review for Takeda’s cTTP treatment

May 17, 2023
Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …

News

RadioMedix and Orano Med complete patient enrolment for neuroendocrine cancer trial

May 16, 2023
Medical Communications Oncology, Orano Med, RadioMedix, neuroendocrine cancer, oncology

US-based RadioMedix and French Orano Med, two clinical stage radiopharmaceutical companies, have announced that the last patient has been enrolled …

News

Nido Biosciences raises $109m in funding for neurological diseases treatments

May 16, 2023
Sales and Marketing Financing, Neurology, Nido Biosciences, funding, neurology

US-based clinical-stage company Nido Biosciences has announced that is has received $109m in Seed, Series A and Series B financings, …

News

Astellas and Sony enter collaborative research agreement

May 16, 2023
Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement

Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …

News

uniQure announces sale of royalty interest in Hemgenix for up to $400m

May 16, 2023
Sales and Marketing Haematology, Hemgenix, haemophilia, royalties, uniQure

uniQure has announced that it has entered a definitive agreement to sell a portion of the royalty rights due to …

News

LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC

May 15, 2023
Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license …

News

Relief Therapeutics awarded approval from Swissmedic for new GMP-compliant laboratory

May 15, 2023
Research and Development GMP, Relief Therapeutics, Swissmedic, laboratory

Swiss biopharmaceutical company Relief Therapeutics has announced that its state-of-the-art R&D laboratory in Balerna, Switzerland, has been audited and approved …

News

NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis

May 15, 2023
Medical Communications NHS, NICE, Virology, hepatitis

The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta …

News
hal-gatewood-_jbclosdsd4-unsplash

FDA approves new nonhormonal medication for menopause hot flashes

May 15, 2023
Medical Communications FDA, HRT, Veozah, hot flashes, menopause

The US Food and Drug Administration (FDA) has announced its approval of Veozah (fezolinetant), an oral medication to treat moderate …

News

FDA relaxes blood donation regulations for MSM

May 12, 2023
Medical Communications FDA, HIV, HIV/AIDS, blood donation

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …

News
robina-weermeijer-ihfopazzjhm-unsplash_5

Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies

May 12, 2023
Sales and Marketing Angelini Pharma, JCR Pharmaceuticals, Neurology, epilepsy

Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for …

News

Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug

May 12, 2023
Medical Communications Bellerophon Therapeutics, Cardiology, clinical trial, lung disease

US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed its phase 3 REBUILD study, …

News

FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment

May 12, 2023
Research and Development ARS Pharmaceuticals, Allergic Disorders, FDA, allergy

US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s Pulmonary-Allergy Drug Advisory Committee (PADAC) …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026